Biopsy Findings in Renal Allograft Dysfunction in a Live Related Renal Transplant Program

Javed I Kazi and Muhammed Mubarak*

Department of Histopathology, Sindh Institute of Urology and Transplantation, Karachi

Abstract

Background: There is little information in literature on renal allograft biopsy findings in renal allograft dysfunction in live related renal transplant recipients.

Material and Methods: A retrospective review of 1210 renal allograft biopsies from 575 renal transplant patients was carried out over a period of seven years from June 1997 till December 2004. The demographic, clinical, laboratory and biopsy findings were collected and analyzed.

Results: A total of 1210 graft biopsies were performed on 575 patients. The mean age of recipients and donors was 29.2±9.7 years, and 35.7±10.5 years, respectively. The males were predominant among recipients (76.7 vs. 23.3%), while among donors they only slightly outnumbered females (51.8 vs. 48.2%).

Regarding pathological lesions, acute rejection was seen in 292 (24%) cases, followed by acute tubular injury and cyclosporine A (CsA) toxicity, found in 281 (23.2%) and 134 (11%) cases respectively. Chronic allograft nephropathy (CAN) with variable degree of tubular atrophy was seen in 361 (29.6%) cases. Seventy nine cases (6.5%) of acute pyelonephritis were detected on graft biopsies. A number of rare lesions were also found, including 13 (1.07%) cases of recurrent/de novo renal disease, and 13 (1.07%) of polyoma virus infection. Five cases of CsA induced hemolytic uremic syndrome (HUS) were also noted.

Conclusion: In conclusion, the incidence of acute rejection is low in our patients as compared to cadaveric renal transplant recipients as reported in Western studies and CsA toxicity is more common. Recurrent/de novo renal disease is uncommon in our patients.

Keywords: Allograft biopsy; Immunosuppression; Renal transplantation; Acute rejection; Cyclosporine toxicity

Introduction

Renal transplantation is the treatment modality of choice for patients with end-stage renal disease (ESRD) throughout the world [1]. The short-term renal transplant outcome has improved markedly during the last few decades due to improved surgical techniques, better medical care, prevention and treatment of infections, but above all, due to advancements in the field of immunosuppressive treatment [1]. Despite the above accomplishments, renal allograft dysfunction is still common after transplantation and may be caused by acute rejection, chronic rejection, calcineurin inhibitor (CNI) toxicity, infections and other rare causes such as recurrence of original renal disease. Each of the above causes of renal allograft dysfunction requires different therapeutic approach and hence accurate diagnosis is essential for the optimal management of the patients [2]. Clinical diagnosis is unreliable as shown by several studies reporting inability to accurately predict the cause of graft dysfunction in 40 to 70% of cases based on the clinical criteria alone [3-7]. Renal allograft biopsy is the gold standard to accurately establish the cause of renal allograft dysfunction [3,8,9]. It is generally felt that the causes of graft dysfunction vary in live related vs. cadaveric renal transplant settings as well as in different immunosuppressive protocols [10-21]. There are also center to center, and inter-institutional variations in the quality and the incidence of rejection [22-26]. There are very few studies exclusively on the causes of graft dysfunction in a live related renal transplant program [10-15].

The estimated incidence of ESRD in Pakistan is 100 per million population (pmp), with approximately 18,000 new cases each year. More than 90% of the ESRD population in this country is disfranchised from renal replacement therapy (RRT), 10% receive dialysis and 4–5% receive transplants at a rate of <5 pmp [16].

We undertook this preliminary study to evaluate the causes of renal graft dysfunction as detected on renal allograft biopsies in a fairly large cohort of live related renal transplant patients and to compare our findings with those in the literature.

Materials and Methods

A retrospective review of 1210 biopsies from 575 renal transplant patients was carried out over a period of seven years from June 1997 till December 2004. Following data items were collected from a review of original renal allograft biopsy request forms and clinical charts; demographics of recipients and donors, donor source and relation, human leukocyte antigen (HLA match), and allograft biopsy findings. Renal allograft biopsies were performed when there was unexplained graft dysfunction (rise in serum creatinine of ≥ 20% over baseline) and/ or proteinuria, fulfilling the established indications of graft biopsies [26,27]. Two cores of renal graft tissue are obtained with automated biopsy gun under real-time ultrasound guidance. In cases with proteinuria or strong clinical suspicion for acute humoral rejection (AHR), an additional core was obtained for immunofluorescence, C4d, and electron microscopy (EM) [28]. The cores for light microscopy (LM) were fixed in 10% buffered formalin and processed for paraffin

*Corresponding author: Dr. Muhammed Mubarak, Associate professor, Department of Histopathology, Sindh Institute of Urology and Transplantation, Karachi-74200, Pakistan, Tel: 009221 99215752; Fax: 009221 32762165; E-mail: drmubarakskiut@yahoo.com

Received September 26, 2011; Accepted October 31, 2011; Published November 03, 2011


Copyright: © 2012 Kazi JI, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
embedding. The biopsies are processed and reported on the same day with urgent processing and preparation of the tissue, and appropriate management instituted. A set of ten slides with multiple serial sections were cut and stained with hematoxylin and eosin (H&E), periodic acid-Schiff reagent (PAS), trichrome and silver stains as recommended in Banff schema [27]. The histological changes were interpreted and classified according to Banff 97 working classification of renal allograft pathology [27].

**Immunosuppression protocol**

The immunosuppressive drugs were started a day before transplantation and all patients received standard triple drug immunosuppression in standard dosages: cyclosporine/FK506, azathioprine/mycophenolate mofetil (MMF), and steroids [10].

Patients with high panel reactive antibodies (PRA) or cadaveric transplants, received induction therapy with antithymocyte/antilymphocyte globulin while other high-risk groups (second transplant, spousal transplants, historical high PRA) received Interleukin-2 (IL-2) receptor blockers.

**Statistical analysis**

Statistical analysis was carried out using IBM compatible SPSS for Windows version 10 (SPSS, Chicago, IL, USA). Simple descriptive statistics such as mean ± standard deviation (SD) were used for continuous variables such as age and clinical and laboratory parameters. Numbers (percentages) were used for categorical data, such as biopsy diagnoses.

**Results**

A total of 1210 graft biopsies were performed in 575 patients from June 1997 to December 2004 at a rate of 2.1 biopsies per patient. The demographic data of the recipients, the donors and the donor-recipient relationship are given in Tables 1, and 2 respectively. The renal allograft transplant and the most frequent clinical question for which allograft biopsies are performed. It was found in 24% of our patients. This is low as compared with the prevalence of around 40% noted in the earlier studies and studies on the cadaveric transplants [6,7]. However, the rates are comparable to those found in other living related renal transplant studies [10,11]. In the Indian study, acute rejection was observed in 27.3 % of cases [10]. In the majority of our cases, AR was of the tubulo-interstitial or cellular type, of milder phenotype, and belonged to IA category of Banff classification, as shown in Table 4 [27,28]. In a small but significant number of cases (11.6%), the rejection process was of the borderline category according to Banff 97 classification. Almost all of these cases were treated with methyl prednisolone pulse and responded with a decline of serum creatinine to pretreatment levels (unpublished data). Both the above findings may be the result of a highly pro-active renal allograft biopsy approach adopted at our center. The diagnosis of early acute cellular rejection is often challenging and may be missed if Banff criteria are applied [22-25,29]. Use of a computer-based artificial neural network such as Bayesian

<table>
<thead>
<tr>
<th>Pathologic lesions</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active / acute rejection</td>
<td>292</td>
<td>24.1</td>
</tr>
<tr>
<td>Cyclosporine toxicity</td>
<td>134</td>
<td>11.0</td>
</tr>
<tr>
<td>Acute tubular injury</td>
<td>281</td>
<td>23.2</td>
</tr>
<tr>
<td>Acute pyelonephritis</td>
<td>79</td>
<td>6.5</td>
</tr>
<tr>
<td>Interstitial fibrosis/tubular atrophy</td>
<td>361</td>
<td>29.8</td>
</tr>
<tr>
<td>No significant pathology</td>
<td>34</td>
<td>2.8</td>
</tr>
<tr>
<td>Others</td>
<td>29</td>
<td>2.4</td>
</tr>
<tr>
<td>Total</td>
<td>1210</td>
<td>100</td>
</tr>
</tbody>
</table>

Table 3: Major categories of pathological lesions on 1210 renal allograft biopsies from 575 patients.

**Discussion**

This is one of the largest studies in the literature on the spectrum of pathological changes seen on renal allograft biopsies in live related renal transplant patients from a single center in Pakistan. The findings from this study are an important contribution to the existing sparse literature on this subject, especially in the context of the live related renal transplant program.

The demographic profile of the recipients and donors is more or less similar to that reported from neighboring country [10,11]. However, the donor source in nearly all of our cases was live related. In one Indian study, more than 70% of donors were live related (LRD) and the remaining were live unrelated (LURD) and cadaveric sources [10]. Another Indian study also reported almost half of transplants from LRDs and remaining from LURDs [11].

Acute rejection (AR) is the most dreaded complication of any allograft transplant and the most frequent clinical question for which allograft biopsies are performed. It was found in 24% of our patients. This is low as compared with the prevalence of around 40% noted in the earlier studies and studies on the cadaveric transplants [6,7]. However, the rates are comparable to those found in other living related renal transplant studies [10,11]. In the Indian study, acute rejection was observed in 27.3% of cases [10]. In the majority of our cases, AR was of the tubulo-interstitial or cellular type, of milder phenotype, and belonged to IA category of Banff classification, as shown in Table 4 [27,28]. In a small but significant number of cases (11.6%), the rejection process was of the borderline category according to Banff 97 classification. Almost all of these cases were treated with methyl prednisolone pulse and responded with a decline of serum creatinine to pretreatment levels (unpublished data). Both the above findings may be the result of a highly pro-active renal allograft biopsy approach adopted at our center. The diagnosis of early acute cellular rejection is often challenging and may be missed if Banff criteria are applied [22-25,29]. Use of a computer-based artificial neural network such as Bayesian
Belief Network (BBN) approach using multiple pathology variables has been shown to increase the accuracy of diagnosis of early acute cellular rejection [22-25]. The diagnosis of acute vascular rejection (AVR) is often straight forward. This type of rejection was less common in our series, being detected in approximately one fifth of AR cases. Similar to cellular rejection, AVR was also mild in the majority of cases. Most cases of AVR belonged to IIA or IIB category. Very few cases of type III or transmural AVR were noted, as shown in Table 4. Acute humoral rejection (AHR) was distinctly uncommon in our patients, found in only three cases, which is not surprising given the live related nature of the donors, and first transplants in the vast preponderance of cases in our cohort [28]. The diagnosis of AHR is made according to revised Banff classification taking into account the morphology, C4d positivity and the detection of donor specific antibody by flow cross match [29].

CNI toxicity was also a major cause of allograft dysfunction in the acute setting in our patients. The diagnosis of this complication is often difficult and challenging [2,15,16-19]. The toxicity of the drugs may be caused in the face of normal or even low levels of the drug in the blood. Most of the morphological changes of CNI toxicity are non-specific except for the nodular arteriolar hyalinosis [2]. In many cases, acute tubular injury coupled with dystrophic calcification and isometric vacuolization of tubular epithelial cells was the only evidence of CNI toxicity.

In the long term, the most common cause of graft dysfunction was interstitial fibrosis/tubular atrophy, not otherwise specified (IFTA, NOS). Indeed, the prevalence of this diagnosis in the renal allograft biopsies increases with the prolongation of posttransplant period, as reported by other investigators [30-32]. In majority of the cases, IFTA was of no specific etiology, which is similar to all the previously published studies on this subject [30-32]. IFTA is not a single entity but rather a designation for the chronic changes affecting the parenchyma and may be caused by a large number of injurious agents. Previously IFTA was designated as chronic allograft nephropathy (CAN). The later designation was replaced by a more descriptive term of interstitial fibrosis/tubular atrophy (IF/FA), with a qualifier NOS (not otherwise specified) if no underlying cause is identified in the biopsy material in Banff ’05 update [32].

We also observed a few cases of acute pyelonephritis of bacterial origin on renal allograft biopsies. The urine culture did not reveal bacterial growth in majority of these cases. This is interesting observation and has been reported previously [33]. Probably the infection is of non-communicating type. Among viral causes, polyoma virus was detected in 13 cases. The polyoma virus infection was confirmed by quantitative polymerase chain reaction (PCR) of the urine and serum. This opportunistic infection has emerged as an important cause of renal allograft dysfunction and graft loss in recent years [34]. Other less common causes of renal allograft dysfunction included 13 cases of recurrent/de novo glomerular diseases. A breakdown of these lesions is given in Table 5. The incidence of these lesions also increases with the prolongation of post-transplant duration [35]. In a significant minority of cases, no obvious pathology was detected on allograft biopsies. This may have resulted from inherent sampling error or some other non-parenchymal cause for the graft dysfunction. However, in an overwhelming majority of cases, the renal allograft biopsy was of immense help in the correct diagnosis and management of renal transplant patients.

In conclusion, the study defines the causes of graft dysfunction as detected on indicated graft biopsies in a large cohort of live related renal transplant patients. The incidence of acute rejection is low in

### Table 4: Breakdown of the 292 cases of acute/active rejection according to Banff classification.

<table>
<thead>
<tr>
<th>Types of rejection</th>
<th>Numbers</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibody mediated rejection</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Borderline rejection</td>
<td>34</td>
<td>11.6</td>
</tr>
<tr>
<td>Tubulointerstitial rejection</td>
<td>198</td>
<td>67.8</td>
</tr>
<tr>
<td>IA</td>
<td>169</td>
<td>57.8</td>
</tr>
<tr>
<td>IB</td>
<td>29</td>
<td>9.9</td>
</tr>
<tr>
<td>Vascular rejection</td>
<td>57</td>
<td>19.5</td>
</tr>
<tr>
<td>IIA</td>
<td>43</td>
<td>14.7</td>
</tr>
<tr>
<td>IIIB</td>
<td>10</td>
<td>3.4</td>
</tr>
<tr>
<td>III</td>
<td>4</td>
<td>1.4</td>
</tr>
</tbody>
</table>

### Table 5: Recurrent/de novo renal diseases on 1210 renal allograft biopsies in 575 patients.

<table>
<thead>
<tr>
<th>Pathological lesions</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focal segmental glomerulosclerosis</td>
<td>5</td>
<td>0.4</td>
</tr>
<tr>
<td>IgA nephropathy</td>
<td>3</td>
<td>0.2</td>
</tr>
<tr>
<td>Membranocapillary GN-I</td>
<td>2</td>
<td>0.1</td>
</tr>
<tr>
<td>Focal necrotizing GN</td>
<td>2</td>
<td>0.1</td>
</tr>
<tr>
<td>Fabry’s disease</td>
<td>1</td>
<td>0.08</td>
</tr>
<tr>
<td>Total</td>
<td>13</td>
<td>1.07</td>
</tr>
</tbody>
</table>

References:


